|
1
|
Ferguson SD: Malignant gliomas: diagnosis
and treatment. Dis Mon. 57:558–569. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Onishi M, Ichikawa T, Kurozumi K and Date
I: Angiogenesis and invasion in glioma. Brain Tumor Pathol.
28:13–24. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rampling R, James A and Papanastassiou V:
The present and future management of malignant brain tumours:
surgery, radiotherapy, chemotherapy. J Neurol Neurosurg Psychiatry.
75(Suppl 2): ii24–ii30. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Salhia B, Tran NL, Symons M, Winkles JA,
Rutka JT and Berens ME: Molecular pathways triggering glioma cell
invasion. Expert Rev Mol Diagn. 6:613–626. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Harpold HL, Alvord EC Jr and Swanson KR:
The evolution of mathematical modeling of glioma proliferation and
invasion. J Neuropathol Exp Neurol. 66:1–9. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Okita Y, Narita Y, Miyakita Y, et al:
Pathological findings and prognostic factors in recurrent
glioblastomas. Brain Tumor Pathol. 29:192–200. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park SG, Jung S, Ryu HH, et al: Role of
14-3-3-beta in the migration and invasion in human malignant glioma
cell line U87MG. Neurol Res. 34:893–900. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
de Groot JF and Gilbert MR: New molecular
targets in malignant gliomas. Curr Opin Neurol. 20:712–718.
2007.PubMed/NCBI
|
|
9
|
Bredel M, Bredel C, Juric D, et al:
Functional network analysis reveals extended gliomagenesis pathway
maps and three novel MYC-interacting genes in human gliomas. Cancer
Res. 65:8679–8689. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nager M, Bhardwaj D, Cantí C, Medina L,
Nogués P and Herreros J: β-Catenin signalling in glioblastoma
multiforme and glioma-initiating cells. Chemother Res Pract.
2012:1923622012.
|
|
11
|
Yue X, Lan F, Yang W, et al: Interruption
of β-catenin suppresses the EGFR pathway by blocking multiple
oncogenic targets in human glioma cells. Brain Res. 1366:27–37.
2010.
|
|
12
|
Sikder HA, Devlin MK, Dunlap S, Ryu B and
Alani RM: Id proteins in cell growth and tumorigenesis. Cancer
Cell. 3:525–530. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Perk J, Iavarone A and Benezra R: Id
family of helix-loop-helix proteins in cancer. Nat Rev Cancer.
5:603–614. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Coppe JP, Itahana Y, Moore DH, Bennington
JL and Desprez PY: Id-1 and Id-2 proteins as molecular markers for
human prostate cancer progression. Clin Cancer Res. 10:2044–2051.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gupta GP, Perk J, Acharyya S, et al: ID
genes mediate tumor reinitiation during breast cancer lung
metastasis. Proc Natl Acad Sci USA. 104:19506–19511. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pillai S, Rizwani W, Li X, et al: ID1
facilitates the growth and metastasis of non-small cell lung cancer
in response to nicotinic acetylcholine receptor and epidermal
growth factor receptor signaling. Mol Cell Biol. 31:3052–3067.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vandeputte DA, Troost D, Leenstra S, et
al: Expression and distribution of id helix-loop-helix proteins in
human astrocytic tumors. Glia. 38:329–338. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Benezra R, Davis RL, Lockshon D, Turner DL
and Weintraub H: The protein Id: a negative regulator of
helix-loop-helix DNA binding proteins. Cell. 61:49–59. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kiewitz SD, Kruppa M, Riechers A, König B
and Cabrele C: Recognition of the helix-loop-helix domain of the Id
proteins by an artificial luminescent metal complex receptor. J Mol
Recognit. 21:79–88. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Langlands K, Yin X, Anand G and Prochownik
EV: Differential interactions of Id proteins with
basic-helix-loop-helix transcription factors. J Biol Chem.
272:19785–19793. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xie SQ, Zhang YH, Li Q, et al:
3-Nitro-naphthalimide and nitrogen mustard conjugate NNM-25 induces
hepatocellular carcinoma apoptosis via PARP-1/p53 pathway.
Apoptosis. 17:725–734. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ciarrocchi A, Piana S, Valcavi R, Gardini
G and Casali B: Inhibitor of DNA binding-1 induces mesenchymal
features and promotes invasiveness in thyroid tumour cells. Eur J
Cancer. 47:934–945. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin CQ, Singh J, Murata K, et al: A role
for Id-1 in the aggressive phenotype and steroid hormone response
of human breast cancer cells. Cancer Res. 60:1332–1340.
2000.PubMed/NCBI
|
|
24
|
Guo Q, Guo P, Mao Q, et al: ID1 affects
the efficacy of radiotherapy in glioblastoma through inhibition of
DNA repair pathways. Med Oncol. 30:3252013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ling MT, Wang XH, Zhang XM and Wong YC:
The multiple roles of Id-1 in cancer progression. Differentiation.
74:481–487. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ahmad A, Aboukameel A, Kong D, et al:
Phosphoglucose isomerase/autocrine motility factor mediates
epithelial-mesenchymal transition regulated by miR-200 in breast
cancer cells. Cancer Res. 71:3400–3409. 2011. View Article : Google Scholar
|
|
27
|
Wells A, Yates C and Shepard CR:
E-cadherin as an indicator of mesenchymal to epithelial reverting
transitions during the metastatic seeding of disseminated
carcinomas. Clin Exp Metastasis. 25:621–628. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Borkar SA, Lakshmiprasad G, Subbarao KC,
et al: Giant cell glioblastoma in the pediatric age group: Report
of two cases. J Pediatr Neurosci. 8:38–42. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qi S, Song Y, Peng Y, et al: ZEB2 mediates
multiple pathways regulating cell proliferation, migration,
invasion, and apoptosis in glioma. PLoS One. 7:e388422012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cheng YJ, Tsai JW, Hsieh KC, et al: Id1
promotes lung cancer cell proliferation and tumor growth through
Akt-related pathway. Cancer Lett. 307:191–199. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tobin NP, Sims AH, Lundgren KL, Lehn S and
Landberg G: Cyclin D1, Id1 and EMT in breast cancer. BMC Cancer.
11:4172011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Meng Q, Jia Z, Wang W, Li B, Ma K and Zhou
C: Inhibitor of DNA binding 1 (Id1) induces differentiation and
proliferation of mouse embryonic carcinoma P19CL6 cells. Biochem
Biophys Res Commun. 412:253–259. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Geng H, Rademacher BL, Pittsenbarger J, et
al: ID1 enhances docetaxel cytotoxicity in prostate cancer cells
through inhibition of p21. Cancer Res. 70:3239–3248. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Anido J, Sáez-Borderías A, Gonzàlez-Juncà
A, et al: TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high)
Glioma-Initiating Cell Population in Human Glioblastoma. Cancer
Cell. 18:655–668. 2010.
|
|
35
|
Barrett LE, Granot Z, Coker C, et al:
Self-renewal does not predict tumor growth potential in mouse
models of high-grade glioma. Cancer Cell. 21:11–24. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sarmiere PD and Bamburg JR: Regulation of
the neuronal actin cytoskeleton by ADF/cofilin. J Neurobiol.
58:103–117. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nager M, Bhardwaj D, Canti C, et al:
β-catenin signaling in glioblastoma multiforme and
glioma-initiating cells. Chemother Res Pract. 2012:1923622012.
|
